Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.

Administration of sunitinib 1 h before each dose of radiation did not augment radiation induced tumor growth delay (AGD 20.7 ± 5.6 days); however sunitinib treatment initiated 24 h following the last dose of radiation did provide additional growth delay (AGD 38.0 ± 8.3 days) but this increase in AGD did not reach statistical significance when compared to radiation alone ( p = 0.15).

also in 111,027 other papers